MOLECULAR ATLAS · VARIANT CARD

WFS1 V106E — Wolframin

Valine → Glutamic acid at position 106. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.912, DynaMut2 ΔΔG -1.49 kcal/mol (destabilising).

IDENTITY

Variant	V106E (p.Valine106Glutamic acid)
DNA change	c.317T>A
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV003371080
Amino acid change	Valine (V) → Glutamic acid (E)

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 106	**92.56** HIGH CONFIDENCE
Domain	N-terminal cytoplasmic (intrinsically disordered)
Position context	N-terminal cytoplasmic (intrinsically disordered)
IDR flag	No — pLDDT well above 50 threshold

> Position 106 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small hydrophobic (valine — branched); the mutant is negatively charged (glutamate — carboxylate). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.912

am_class: **likely pathogenic** — threshold > 0.564

DYNAMUT2 ΔΔG

-1.49 kcal/mol

Destabilising · Job 178092105454

PLDDT (ALPHAFOLD)

92.56

high confidence

CLINICAL EVIDENCE

ClinVar classification — UNCERTAIN SIGNIFICANCE

Review status	criteria provided, single submitter
Last evaluated	2024/03/17 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	V106E is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- (no conditions catalogued)

RESEARCH PATH DECISION TREE

```
ΔΔG < 2 + binding site affected → CATEGORY 3 — docking experiments ΔΔG 2–4 → CATEGORY 2 — pharmacological chaperones ΔΔG > 4 → CATEGORY 1 — gene therapy pLDDT < 50 → CATEGORY 5 — IDR, experimental only Stable fold + functional site hit → CATEGORY 4 — site-specific docking
```

Category 3/4 — Most Druggable

|ΔΔG|=1.49 < 2 kcal/mol (fold intact) + AlphaMissense 0.912 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframin's fold survives this substitution (|ΔΔG|=1.49 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.912. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.
